Wednesday, 19 September 2018

Immatics, Genmab to develop bispecific cancer immunotherapies

12 July 2018 | News

Immatics and Genmab to Combine Proprietary Technologies to Create Transformative Bispecific Therapies against Novel, Proprietary Tumor Targets

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, has entered into a research collaboration and license agreement with Genmab to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.

 

The companies will conduct joint research, funded by Genmab, to combine Immatics’ XPRESIDENT® and Bispecific TCR technology platforms with Genmab’s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology.

 

The companies will exclusively discover and develop immunotherapies directed against three proprietary targets, which were discovered and developed by Immatics’ XPRESIDENT® technology.

 

Genmab has the option to exclusively license up to two additional targets to expand the partnership at predetermined economics.

 

Genmab will be responsible for development, manufacturing and worldwide commercialization. Immatics will have an option to contribute certain promotion efforts at predetermined levels in selected countries in the EU.

 

Under the terms of the agreement, Immatics will receive an upfront fee of $54 million and is eligible to receive up to $550 million in development, regulatory and commercial milestone payments for each product and tiered royalties up to a double-digit percentage of net sales.

 

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Click Here!

Survey Box

Is ageing Asia spurring rise in assistive robots and tele-healthcare?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls